Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Young-Mo Yang & Eun Joo Choi. (2017) Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. Therapeutics and Clinical Risk Management 13, pages 477-497.
Read now
Read now
Linda Henry & Zobair Younossi. (2016) Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research 16:6, pages 659-665.
Read now
Read now
Articles from other publishers (4)
Ana D Vega, Lauren M Hynicka, Kimberly Claeys, Joel V Chua & Emily L Heil. (2019) Effectiveness of 8 Weeks of Ledipasvir/Sofosbuvir for Hepatitis C in HCV–HIV-Coinfected Patients. Antiviral Therapy 24:1, pages 11-17.
Crossref
Crossref
Aabha Nagral, Smita Sawant, Nishtha Nagral, Pathik Parikh, Priya Malde & Rashid Merchant. (2017) Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major. Journal of Clinical and Experimental Hepatology 7:3, pages 172-178.
Crossref
Crossref
Kiran Joglekar, James D. Eason & Miklos Z. Molnar. (2017) Do we really need more evidence to use hepatitis C positive donor kidney more liberally?. Clinical Kidney Journal 10:4, pages 560-563.
Crossref
Crossref
Ying-Hong Li, Zhou-Yi Wu, Sheng Tang, Xin Zhang, Yan-Xiang Wang, Jian-Dong Jiang, Zong-Gen Peng & Dan-Qing Song. (2017) Evolution of matrinic ethanol derivatives as anti-HCV agents from matrine skeleton. Bioorganic & Medicinal Chemistry Letters 27:9, pages 1962-1966.
Crossref
Crossref